SLC5A2 and COVID-19: By improving the abnormal apelin-ACE2 signaling, SGLT2 inhibitors might represent a potential therapeutic approach in ameliorating the cardiorenal dysfunction in acute COVID-19 patients and serve as a potential effective LCS treatment option [79].